Clinical Trials Browser

Phase 2 × Atorvastatin × 90 days × Clear all

NCT04915183 2026-06-05

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Phase 2 Recruiting

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss